FDA Panel Supports Expanded HF Role for Sacubitril/Valsartan FDA Panel Supports Expanded HF Role for Sacubitril/Valsartan

The advisors overwhelmingly favored an expanded indication, which they then narrowed to what guidelines call ' mid-range LVEF. ' But there was debate about what it should be called in labeling.Medscape Medical News

Source: Medscape Cardiology Headlines - December 16, 2020 Category: Cardiology Tags: Cardiology News Source Type: news